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However, despite initial response, after a 
variable interval the disease eventually pro-
gresses to castration-resistant prostate cancer 
(CRPC), usually by a rise in prostate-specific 
antigen (PSa).3 recently, clinical and preclini-
cal studies have demonstrated that the andro-
Prostate cancer is the second most frequent cancer in men, with 1.1 million new cases 
estimated to occur yearly.1 The standard treat-
ment of patients with advanced prostate cancer 
is androgen deprivation therapy, to reduce tes-
tosterone production by testes.2
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BacKgroUND: abiraterone acetate, approved for patients with metastatic castration-resistant prostate cancer 
(mcrPc), blocks androgen byosinthesis. We aimed to describe changes determined by abiraterone in hormones implied 
in steroid biosynthesis, exploring association between hormonal levels and drug activity.
MeTHoDS: Patients with mcrPc, receiving standard abiraterone + prednisone after docetaxel failure, were studied. 
We determined serum levels of progesterone, 17oH-progesterone, cortisol, acTH, DHea-sulphate, androstenedione, 
testosterone, sex hormone-binding globulin, aldosterone, plasma renin activity, and cholesterol, baseline and every 12 
weeks. for each hormone, association with treatment activity was tested 1) comparing baseline values in responders vs. 
non-responders; 2) comparing progression-free survival (PfS) of patients with baseline low vs. high values; 3) comparing 
values after 12 weeks in responders vs. non-responders.
reSUlTS: forty-nine patients were analyzed; 26 patients (53.1%) experienced PSa response. Baseline values of all 
hormones were not statistically different between responders and non-responders. for all hormones, PfS difference of 
patients with low vs. high baseline values was not statistically significant. Several hormones showed significant and sus-
tained changes vs. baseline, but all significant changes were similar between responders and non-responders.
CONCLUSIONS: This analysis does not suggest a significant association between baseline hormonal values, or changes 
induced by abiraterone, and treatment activity.
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ceiving abiraterone. in addition, we conducted 
an exploratory analysis to evaluate the associa-
tion between hormonal values (at baseline and 
during treatment) and drug activity, in terms 
of PSa response rate and progression-free sur-
vival (PfS). The aim of this exploratory study 
was to generate hypothesis about the use of se-
rum biomarkers to predict abiraterone activity, 
before or early after treatment start. This infor-
mation could be of great value toward treat-
ment personalization and optimization of the 
use of abiraterone.
Materials and methods
Aim of the study
Main objective of this analysis was to de-
scribe the changes in serum hormonal values 
during treatment with abiraterone acetate plus 
prednisone, in metastatic crPc patients pro-
gressing after first line chemotherapy. Second-
ary objective was an explorative analysis of the 
association between hormonal baseline values 
and treatment activity, and between changes in 
hormonal values and treatment activity. The 
following analytes were evaluated:
1) glucocorticoid hormone: cortisol;
2) progestagens: progesterone, 17hydroxy-
progesterone;
3) sex hormones: testosterone, androsten-
edione, DHea sulfate (DHea-S);
4) hormones involved in mineralcorticoid 
pathway: Pra and aldosterone;
5) lipid profile: total cholesterol, low-den-
sity lipoprotein (lDl) cholesterol and high-
density lipoprotein (HDl) cholesterol;
6) acTH and SHBg were evaluated.
Patients
The analysis was conducted on a series of 
patients with mcrPc, with disease progres-
sion following first-line chemotherapy with 
docetaxel, treated with abiraterone acetate 
within the expanded access Program and ac-
cording to declaration of Helsinki. Patients 
were recruited between June 2010 and De-
cember 2010 at a single institution (Medical 
gen receptor (ar) plays a critical role after 
disease progression, and continues to drive the 
proliferation of crPc.4 Several studies have 
shown that extragonadal androgen production, 
at adrenal and/or intratumor level, is one of 
the mechanisms allowing tumor progression 
despite castration level of serum testosterone.5 
This production is obtained by up-regulation 
of cytochrome P450–17α-hydroxylase/17,20-
lyase (cYP17a1), a key enzyme in the pro-
duction of androgens and estrogens, both in the 
adrenal glands and in tumor tissue.6 abirater-
one acetate is the prodrug of abiraterone, that 
blocks cYP17, with 17α-hydroxylase/17,20-
lyase inhibitory properties, and inhibits both 
testicular, adrenal and intratumor androgen 
production. Two randomized phase iii trials 
have shown that abiraterone improves over-
all survival (oS) in patients with metastatic 
crPc (mcrPc), both pretreated with chemo-
therapy and chemotherapy-naïve.7, 8 although 
this drug is a significant therapeutic advance, 
about one third of patients receiving abirater-
one after docetaxel failure shows intrinsic, 
primary resistance.9 furthermore, virtually all 
patients, after a widely variable duration of 
response, develop acquired resistance. Nowa-
days, mechanisms of resistance have not been 
well defined yet. Recent studies have focused 
on the following mechanisms of resistance: 
systemic and intratumor androgens biosyn-
thesis up-regulation,10 alternative pathways of 
androgens production,11 ar gene mutations,12 
amplification/over-expression and AR splice 
variants expression.13, 14 currently, there are 
no validated serum biomarkers that can predict 
mechanisms of resistance or the outcome of 
patients receiving abiraterone. Therefore, the 
absence of validated predictive factors for abi-
raterone, together with the recent availability 
of other effective treatments, such as cabazi-
taxel 15 or enzalutamide,16 make treatment de-
cisions about the best drug (or sequence) re-
ally challenging. in this study, we described 
changes of hormones involved in steroid hor-
mones synthesis and evaluated adrenocortico-
tropic hormone (acTH), sex hormone binding 
globulin (SHBg), plasma renin activity (Pra) 
and lipid profile, in patients with mCRPC re-
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cT kit– raDiM); cortisol (cortisol ria cT 
kit – raDiM); aldosterone (alDoSTeroNe 
Maia ria kit –aDalTiS); 17hydroxypro-
gesterone (17 HYDroXYProgeSTeroNe 
ria cT kit–raDiM); Pra (reNcTK – Di-
aSoriN); SHBg, DHea-S and androstene-
dione were measured by chemiluminescent 
enzyme immunoassay (cleia) method with 
immulite tool 2000 Siemens. Progesterone and 
testosterone were evaluated by chemilumi-
nescent Microparticle immunoassay method 
(cMia), with architect company abbott Di-
agnostics.
Statistical analysis
all the statistical analyses described in this 
paper were not pre-planned, so there was no a 
priori calculation of sample size and statistical 
power.
for each analyte, samples obtained at each 
time-point during treatment (after 3 cycles, 
after 6 cycles, after 9 cycles, after 12 cycles) 
were compared to baseline values by Wilcox-
on matched-pairs test.
for each analyte, association between hor-
mones and treatment activity was tested in 3 
different exploratory analyses:
1) comparing baseline hormonal values of 
responders (i.e. those patients with PSa reduc-
tion during abiraterone treatment ≥50%) vs. 
non-responders (i.e. those patients with PSa 
reduction during abiraterone treatment <50%). 
The distribution of baseline hormonal values 
was graphically represented by box plots, and 
statistical significance of the difference be-
tween the 2 groups was tested by non paramet-
ric Wilcoxon test;
2) comparing PfS of patients with baseline 
hormonal value ≤ median value vs. patients 
with baseline hormonal value higher than me-
dian value. The PFS was defined as the time 
from the beginning of treatment until progres-
sion or date of last follow-up for patients with-
out progression at the time of analysis. PfS 
was evaluated using Kaplan-Meier methods 
and the two groups were compared by long-
rank test. Hazard radio (Hr) of progression 
was calculated using cox model, with catego-
oncology Division, “San luigi gonzaga” 
Hospital, orbassano, Turin, italy). Main inclu-
sion criteria in the expanded access Program 
were: men aged 18 years and above with histo-
logically confirmed prostate cancer; previous 
treatment with docetaxel; progressive disease 
defined as rising PSA according to Prostate 
cancer Working group (PcWg2) criteria 
or radiographic progression in soft tissue or 
bone with or without biochemical progression; 
ECOG performance status (PS) ≤2; level of 
testosterone <50 ng/dL; hemoglobin ≥9 g/dL; 
platelet count ≥100,000/mm3; serum albumin 
≥3.0 g/dL; normal liver and kidney function; 
serum potassium ≥3.5 mEq/L; able to swal-
low the study drug whole as a tablet; signed 
informed consent.
exclusion criteria included: patients already 
treated with abiraterone acetate; concurrent 
serious disease or uncontrolled infection; un-
controlled hypertension; active or symptom-
atic viral hepatitis or chronic liver disease; 
history of gastrointestinal disorders that may 
interfere with drug absorption; history of pitu-
itary or adrenal dysfunction; clinically signifi-
cant heart disease; brain metastases; grade >2 
treatment-related toxicity from prior therapy; 
previous treatment with azoles (fluconazole, 
itraconazole, ketoconazole) within 4 weeks 
before starting abiraterone acetate; administra-
tion of an investigational therapeutic within 30 
days; psychiatric illness.
Treatment and procedures
abiraterone acetate was administered oral-
ly, in 28-day cycles, at 1000 mg per day, with 
prednisone (5 mg twice a day), until disease 
progression or unacceptable toxicity. During 
treatment, clinical exam and blood test were 
performed every 2 weeks. Serum hormonal 
levels were evaluated before starting treat-
ment, after 3 cycles (12 weeks), and every 3 
cycles thereafter, until disease progression.
Measurement of analytes
The following hormones were measured 
by radioimmunoassay: acTH (acTH irMa 
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gleason score (gS) was evaluated according 
to NCCN classification: GS was 2-6, 7, 8-10 
and unknown in 6 (13.3%), 16 (35.6%), 23 
(51.1%) and 4 patients (8.1%), respectively. 
at the evaluation before starting treatment 
with abiraterone, 40 patients (82%) had bone 
lesions, 27 patients (55%) lymph nodes me-
tastases, 5 patients (10%) lung metastases, 7 
patients (14%) loco-regional recurrence and 2 
patients (45%) secondary lesions in other sites.
Activity of treatment
Compliance to treatment was verified in 
all patients. in the whole series of 49 treated 
patients, PSa response rate was 53.1% and, 
with 43 events recorded, median PfS was 10.2 
months. in detail, 95.9%, 71.4% and 39.5% of 
patients were without progression after 3, 6 
and 12 months, respectively. Median follow-
up, according to Schemper method (reverse 
Kaplan Meier) was 23.8 months, with 6 cen-
sored patients. Decreasing of number of pa-
tients was due to PSa progression and not to 
lost at follow-up.
Hormonal levels
Baseline values for all analytes are re-
ported in Table ii. changes in glucocorticoid 
hormone and progestagens are described in 
Table ii and in figure 1 (panels 1a-1D). a 
progressive, statistically significant decrease 
of cortisol was observed. Median cortisol 
value was 13.6 mcg/dl at baseline, 3.60 af-
ter three months (P=0.001) and 1.50 mcg/dl 
after twelve months (P=0.008). Progesterone 
was statistically increased after three and nine 
months: median value was 0.10 ng/ml at base-
line, 1.40 ng/ml (P=0.001) after three months 
and 1.70 ng/ml (P=0.001) after nine months. 
17hydroxyprogesterone was not significantly 
changed during treatment. a statistically sig-
nificant increase in ACTH was observed after 
three months of treatment. Median acTH val-
ue was 27 pg/ml at baseline and 29.3 pg/ml 
after three months (P=0.047). changes in sex 
hormones are described in Table ii and figure 
1 (panels 1E-1H). A statistically significant 
ry of baseline hormonal value (high vs. low) 
as variable, not adjusted for other prognostic 
variables;
3) comparing values after 12 weeks of treat-
ment with abiraterone, adjusted by baseline 
values, in responders vs. non-responders pa-
tients. in this analysis, only patients with data 
available about hormonal value at baseline and 
after 12 weeks were included. The distribution 
of values was graphically represented by box 
plots, and the statistical significance of the dif-
ference in values after 12 weeks between the 2 
groups was tested in a linear model, using the 
baseline value as covariate.
Statistical analyses were performed using 
the S-Plus 6.1 Professional edition for Win-
dows and software SPSS (version 21). for all 
the analysis, statistical significance was set at 
P=0.05 and, given the exploratory aim, no cor-
rection for multiplicity was applied.
Results
forty-nine consecutive patients were en-
rolled in this study. Demographic data are 
reported in Table i. Median age was 70 years 
(range, 56-85 years); ecog PS was 0, 1 
and 2 in 61%, 36% and 6% patients, respec-
tively. Median serum PSa level at baseline 
was 116.95 ng/ml (range: 2.48-5580 ng/ml). 
Table I.—Main baseline characteristics of patients 
treated with abiraterone (N.=49).
age
Median (range) 70 yrs (56-85)
ecog performance status
0 30 (61%)
1 16 (33%)
2 3 (6%)
gleason score (n.a. 4 patients)
<=6 6 (13%)
7 16 (36%)
8 10 (22%)
9 13 (29%)
Baseline PSa
Median (range) 116.95 (2.48-5580)
Sites of disease
Bone 40 (82%)
lymph-nodes 27 (55%)
lung 5 (10%)
local (prostate) 7 (14%)
other 2 (4%)
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cantly changed. The levels of total cholesterol, 
HDl cholesterol and lDl cholesterol did not 
change significantly during treatment Table II.
Association between hormones and treatment 
activity
comparison of baseline values between 
responders and non-responders is reported in 
figure 2. for all the analytes, baseline values 
were not statistically different between re-
sponders and non-responders.
comparison of PfS between patients with 
low basal values and patients with high base-
line values, for each analyte, is reported in 
figure 3. for all analytes, difference in PfS 
between patients with low baseline values vs. 
patients with high baseline values was not sta-
tistically significant. Comparison of hormonal 
values after 12 weeks between responders and 
non-responders, adjusted by baseline value, 
decrease of DHea-S was observed: median 
DHea-S value was 22.6 mcg/dl at baseline, 
7.5 mcg/dl after three months (P=0.001). a 
significant decrease in androstenedione value 
was observed: median androstenedione value 
was 0.57 ng/ml at baseline vs. 0.15 ng/ml af-
ter three months (P<0.001). Testosterone, that 
was already suppressed at baseline as expect-
ed, remained suppressed according to the cut-
off <50 ng/dL, SHBG value decreased signifi-
cantly during treatment: median SHBg value 
was 48.5 nmol/l at baseline, 40.9 nmol/l after 
3 months (P=0.001) and 39.7 nmol/l after 9 
months (P=0.004). changes in mineralcor-
ticoid hormones are reported in Table ii and 
Figure 1 (panels 1I-1J). A significant increase 
in aldosterone values was observed: median 
aldosterone was 178 pg/ml at baseline, 246 
pg/ml after three months (P=0.009), and val-
ues increased significantly even after six and 
nine months. The PRA activity was not signifi-
Table II.—Hormonal levels at baseline and during treatment with abiraterone.*
Hormone
Baseline after 3 cycles after 6 cycles after 9 cycles after 12 cycles
N. 
pts median
N. 
pts median P
N. 
pts median P
N. 
pts median P
N. 
pts median P
Progesterone 43 0.10
(0.005-5.5)
39 1.40
(0.10-9.30)
<0.001 25 1.20
(0.10-13.0)
<0.001 20 1.70
(0.10-15.0)
0.001 8 1.65
(0.10-14.20)
0.07
17-oH-
progesterone
48 0.60
(0.05-1.90)
47 0.60
(0.05-1.70)
0.62 33 0.50
(0.05-1.60)
0.53 21 0.40
(0.05-1.20)
0.025 9 0.40
(0.05-1.30)
0.48
cortisol 49 13.6
(0.09-27.2)
48 3.60
(0.09-14.30)
<0.001 34 3.06
(0.50-22.1)
<0.001 23 2.89
(0.50-17.5)
<0.001 9 1.50
(0.50-5.26)
0.008
acTH 49 27
(3.1-96.8)
49 29.3
(4.0-193.0)
0.047 35 30.5
(4.0-201.0)
0.26 23 36.0
(4.0-255.0)
0.076 10 33.7
(4.0-243.0)
0.57
DHea 
sulphate
47 22.6
(7.5-125)
47 7.5
(7.5-15.0)
<0.001 32 7.5
(7.5-7.5)
<0.001 21 7.5
(7.5-7.5)
0.003 10 7.5
(7.5-7.5)
0.07
andro-
stenedione
49 0.57
(0.15-1.70)
49 0.15
(0.15-0.15)
<0.001 34 0.15
(0.15-0.15)
<0.001 23 0.15
(0.10-0.15)
<0.001 10 0.15
(0.15-0.15)
0.018
Testosterone 49 0.14
(0.07-0.51)
48 0.23
(0.07-1.35)
<0.001 35 0.29
(0.07-1.10)
0.003 23 0.25
(0.02-1.49)
0.007 10 0.19
(0.03-0.48)
0.86
SHBg 49 48.50
(17-152)
49 40.9
(21.4-89.4)
0.001 35 46.2
(18.2-93.8)
0.042 22 39.7
(25.8-76.8)
0.004 10 45.1
(16.0-65.6)
0.086
aldosterone 49 178
(53-571)
49 246
(39-1205)
0.009 35 261
(72-640)
0.033 23 355
(3.6-1239)
0.016 10 302
(114-594)
0.39
renin (Pra) 49 1.00
(0.2-22.4)
49 1.00
(0.10-60.5)
0.58 35 1.50
(0.20-16.8)
0.92 23 1.30
(0.20-15.0)
0.97 10 2.95
(0.50-9.6)
0.72
cholesterol 
(total)
48 204.5
(113-316)
48 214.5
(103-301)
0.89 34 210.5
(141-315)
0.84 22 224.5
(99-296)
0.81 10 230.5
(106-295)
0.33
HDl 
cholesterol
48 46.5
(28-93)
48 53.0
(30-88)
0.002 34 48.0
(26-85)
0.50 22 43.5
(27-80)
0.53 10 58.0
(26-86)
0.31
lDl 
cholesterol
41 139
(57.1-245)
41 139
(45.2-206)
0.035 30 140.5
(15-229)
0.019 16 144.0
(57.6-190.6)
0.35 9 140.0
(118.0-219.2)
0.51
*only patients with available baseline values are included in this analysis.
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figure 1.—changes in hormonal values during treatment with abiraterone. for each analyte, 2 box plots are depicted: base-
line values (on the left) and values obtained after 12 weeks of treatment (on the right). line in the box: median value; box 
hinges: 25-75th percentile; ends of the segments:10-90th percentile; dots: outliers.
figure 2.—comparison of baseline hormonal values between responders (i.e. those patients with PSa reduction during abi-
raterone treatment ≥50%) and non-responders (i.e. those patients with PSa reduction during abiraterone treatment <50%). 
for each analyte, 2 box plots are depicted: non-responders (on the left) and responders (on the right). line in the box: median 
value; box hinges: 25-75th percentile; ends of the segments: 10-90th percentile; dots: outliers.
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figure 3.—comparison of progression-free survival between patients with low basal values (continuous line) and patients 
with high baseline values (dotted line), for each analyte.
figure 4.—comparison of hormonal values after 12 weeks between responders and non- responders, adjusted by baseline 
value. for each analyte, 4 box plots are depicted from left to right: baseline values in non-responders, values after 12 weeks 
in non-responders, baseline values in responders, values after 12 weeks in responders. line in the box: median value; box 
hinges: 25-75th percentile; ends of the segments: 10-90th percentile; dots: outliers.
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drogen biosynthesis pathway are upregulated. 
Studies in animal models have also shown that 
tumour relapse on abiraterone was associated 
with further up-regulation of intratumor cY-
P17a1 and other key genes involved in intra-
tumor androgen synthesis. resistance to abi-
raterone can be due to activation of alternative 
pathways of androgens synthesis.11 The potent 
inhibition of cYP17a1 induced by abirater-
one causes androgens accumulation upstream 
the enzymatic block, as pregnenolone and pro-
gesterone. Progesterone can be converted to 
5 α-dihydrotestosterone (DHT) by “backdoor 
pathway”.11 This pathway consists in eight en-
zymatic steps that induce DHT synthesis via 
3α-androstanediol production. �oreover, abi-M
raterone does not completely ablate DHea-S, 
which can be transported and metabolized in 
tumoral cells to Dea, a steroid downstream 
of cYP17a1, bypassing the enzymatic block 
caused by abiraterone. To our knowledge, this 
is the first study that evaluated baseline and 
variations in adrenal hormones during treat-
ment with abiraterone, in order to explore their 
impact in terms of prognosis and potential 
mechanisms of resistance. in a retrospective 
analysis of trial coU-aa-301, evaluating the 
baseline serum androgen (testosterone, andros-
tenedione and DHea-S) and their association 
with oS in patients with mcrPc, baseline se-
rum testosterone levels were prognostic of sur-
vival, independent of treatment arm.17 authors 
suggested that testosterone levels may affect 
the study outcomes and represent a more ag-
gressive disease.17 as expected, according to 
potent cYP17a1 block induced by abirater-
one, we showed an important inhibition of tes-
tosterone precursors synthesis and an increase 
of steroids concentrations upstream the enzy-
matic block, as progesterone. our data also 
demonstrated a significant reduction of cortisol 
levels that was not associated with an increase 
of ACTH. These results confirm that, despite 
the dramatic serum cortisol reduction induced 
by abiraterone, concomitant prednisone is effi-
cacious in preventing acTH elevation. Moreo-
ver, we investigated relationship between treat-
ment response and hormonal values at baseline 
and during abiraterone treatment, in order to 
for each analyte, is reported in figure 4. also 
the comparison of patients with early failure 
vs. long-responders patients did not show any 
significant difference in baseline hormonal 
values (data not shown).
for all analytes, the difference in the value 
after 12 weeks of treatment between respond-
ers and non-responders was not statistically 
significant. �hen a signifi cant change com-
pared to baseline was described, this change 
was similar between responders and non-re-
sponders.
Discussion
in this study, our aim was to describe the 
changes of hormonal levels during treatment 
with abiraterone in mcrPc patients progress-
ing after docetaxel therapy, and to explore a 
correlation between baseline hormonal values, 
hormonal changes during treatment and activ-
ity of abiraterone. compared to baseline val-
ues, we found statistically significant changes 
in several hormones: among others, a signifi-
cant increase in the level of progesterone and 
aldosterone and a significant decrease in the 
level of cortisol, DHea-S and androstenedi-
one. for all hormones, baseline values were 
not statistically different between responders 
and non-responders, and difference in PfS be-
tween patients with low baseline values and 
patients with high baseline values was not sta-
tistically significant. Several hormones showed 
significant and sustained changes compared to 
baseline, but all significant changes were simi-
lar between responders and non-responders. as 
demonstrated in randomized trials, abiraterone 
treatment significantly prolongs OS, modifying 
the natural history of mcrPc.7 Nowadays, we 
do not have validate biomarkers which could 
be predictors of response to abiraterone and 
help clinicians to personalize therapy. a better 
understanding of resistance mechanisms to this 
new drug is crucial in order to identify these 
biomarkers. androgens synthesis in prostatic 
cancer cells is an important androgen source 
under the pressure of androgen deprivation 
therapy.10 Preclinical models show that, dur-
ing abiraterone, various genes involved in an-
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arV lacks the ligand-binding domain and is 
able to activate itself in the absence of ligand. 
These arVs may be one major potential mech-
anism of resistance to new ar-targeting drugs. 
arV7 and arV567 are the most clinically 
prevalent splice variants in metastatic crPc.22 
recently antonarakis et al. reported that the 
detection of arVs in circulating tumour cells 
of patients with mcrPc treated by enzaluta-
mide or abiraterone could predict resistance to 
these agents.14 arV-7 positive patients, treated 
with abiraterone, had a dramatically lower PSa 
response rate (0% vs. 68%, P=0,004) and worse 
outcomes compared to arV-7 negative coun-
terpart. Patients arV7-positive, treated with 
enzalutamide, had lower PSa response rates 
(0% vs. 53%, P=0.004) and worse outcomes 
than arV7-negative patients. These data sup-
ported the hypothesis that both intrinsic and 
acquired resistance to these agents may be as-
sociated with arV7. We acknowledge that a 
robust study of the predictive role of baseline 
hormonal values, or their early changes during 
treatment, should be conducted within a ran-
domized controlled trial. However, in the ab-
sence of optimal data, our aim was to perform 
an exploratory analysis, in order to generate 
hypotheses to be subsequently validated. Un-
fortunately, none of the hormones tested appear 
to be strongly related to abiraterone activity, 
neither in terms of baseline values nor in terms 
of early changes during treatment.
Conclusions
in conclusion, this analysis, conducted in 
patients with mcrPc, treated with abiraterone 
in the post-docetaxel setting, failed to identify 
a predictive biomarker in terms of baseline 
value of hormones implied in steroid biosyn-
thesis pathway, or in terms of early modifica-
tion during treatment. in order to allow better 
treatment choices, and optimization of the 
use of abiraterone, it would be important to 
conduct further studies to identify predictive 
markers, and to better understand mechanisms 
of drug resistance. furthermore, it would be 
important to evaluate predictive biomarkers 
also in chemotherapy-naïve patients.
identify a predictive biomarker. although this 
analysis was not pre-planned and character-
ized by a small statistical power, our attempt 
to explore the association between values of 
hormones implied in steroid biosynthesis path-
way and activity of abiraterone did not pro-
duce statistically significant results. our data 
cannot confirm the hypothesis that changes of 
adrenal hormonal levels, induced by cYP17a1 
block, is one of the most important resistance 
mechanisms to abiraterone treatment, because 
changes in hormonal values were similar be-
tween responding and non-responding patients. 
However, these negative results could be due 
to the small number of patients enrolled, but 
also to the complexity of resistance mecha-
nisms. on this point, ryan et al. investigated 
the ability of abiraterone to reduce serum an-
drogens under the lower limit of quantifica-
tion from baseline to week 12 and the relation-
ship between changes in androgen levels and 
PSa response rate in patients with mcrPc, 
enrolled in clinical trial coU-aa-301.18 abi-
raterone treatment significantly reduced the 
mean serum androgens from baseline to week 
12. The reduction of androgens did not predict 
uniformly PSa decline, supporting the hypoth-
esis that progression of mcrPc is also driven 
by ligand-independent mechanisms.18 Preclini-
cal data showed that ar under the pressure of 
androgen deprivation is susceptible to somatic 
changes and aberrant transcription which let it 
responsive to glucocorticoids and progester-
one.19 The increased progesterone levels during 
abiraterone treatment can activate the mutated 
form of ar, causing resistance to abiraterone. 
furthermore, mcrPc has an increased expres-
sion of progesterone receptor (Pr),20 and the 
binding of progesterone can activate transcrip-
tion of androgen-dependent genes. on the basis 
of this preclinical evidence, a phase 1-2 study 
conducted in patients with crPc progressed 
after abiraterone, enzalutamide or two lines 
of chemotherapy showed that Pr inhibition 
by onapristone, a Pr antagonist, is feasible 
and safe.21 Preclinical data also demonstrated 
that abiraterone treatment is associated with a 
3-fold increased expression of both full-length 
ar and truncated ar splice variant (arV).13, 14 
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